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Introduction
Anaphylactic reactions during anesthesia are rare but
may have dramatic and unpredictable consequences;
it may present with severe symptoms such as cardio-
vascular collapse or bronchospasm.1,2 The incidence
of anaphylaxis during anesthesia is very difficult to
estimate.3 The leading causes are neuromuscular block-
ing agents, latex, and antibiotics, followed by other
induction medications. Bronchospasm in association
with anesthesia may appear as an entity in its own right
or may be a component of another problem such as
anaphylaxis.4,5 The key element of the management
of anaphylactic reactions in the operation room is a
collaborative effort between anesthesiologists and
surgeons.
In November 2007, successive cases of broncho-
spasm manifesting as sudden and dramatic increase in
inflation airway pressure and episode of diffuse wheeze
without other anaphylactic symptoms such as urticaria,
angioedema or hemodynamic instability occurred dur-
ing general anesthesia in our institute. Some cases
presented as severe bronchospasm, with difficulty in
ventilation and very high airway resistance. All of the
cases were effectively treated by intravenous steroids
and lidocaine, inhaled or intravenous bronchodilator,
and even intravenous epinephrine. It is of the utmost
importance to clarify the cause of the successive sus-
pected anaphylaxis cases or the interaction between
causative substances. This is also important since pa-
tients and anesthesiologists need to be informed about
exposure to the identified substance(s) and risk factors.
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Therefore, we report herein the investigation and cri-
sis management of this succession of cases of anaphy-
laxis induced by a prophylactic antibiotic.
The goal of this study was to determine the causes
of the suspected anaphylactic reactions and to stop fur-
ther episodes. We investigated all the cases by reviewing
the anesthesia records. The preliminary data revealed
that a prophylactic antibiotic, cephalexin (Roles®; Gentle
Pharmaceutical Corporation Kashin Medicines Co.,
Ltd., Yunlin, Taiwan), which had been administered in
most cases as a prophylactic antibiotic after the induc-
tion of general anesthesia, may have played an impor-
tant role. Anaphylaxis induced by this medication was
highly suspected, and perioperative use of this antibiotic
was reduced after our announcement of the possibility
of it causing bronchospasm during general anesthesia.
Methods
This retrospective study was conducted at Taipei
Veterans General Hospital and was approved by the
hospital’s institutional review board. We carried out a
retrospective survey by reviewing the medical and anes-
thesia records of all patients of ASA Class 1 to 3 who
received general anesthesia at our hospital between
November 1 and November 10, 2007. Demographic
data and information regarding underlying diseases
were collected for each patient, and all substances to
which each patient had been exposed, including intra-
venous and inhalational anesthetic agents for general
anesthesia and prophylactic antibiotics, were recorded.
The interval between endotracheal intubation and an-
tibiotic administration, and the duration of antibiotic
administration were also obtained from the anesthesia
records. The tidal volume was set at 7–10 mL/kg on
the time-cycled ventilator of the anesthesia machine.
Airway pressure after endotracheal intubation and se-
quential changes after the administration of prophylac-
tic antibiotics were collected every 5 minutes during the
whole course of general anesthesia. The prophylactic
antibiotic was selected by the surgeon in each case, and
the diagnosis and management of bronchospasm (ele-
vated airway pressure and auscultated wheezing) were
determined by each patient’s independent attending
anesthesiologist.
Details were obtained regarding the degree of eleva-
tion of airway pressure as compared with after intuba-
tion. In order to identify the severity of bronchospasm
in this study, we divided patients into several groups
by the degree of elevation of inspiratory pressure. The
severity of elevation was graded from 0 to 5, indicat-
ing least to greatest severity [grade 0 = airway pressure
elevation of 0–2 cmH2O; grade 1 = elevation of 3–5
cmH2O; grade 2 = elevation of 6–10 cmH2O; grade
3 = elevation of 11–15 cmH2O; grade 4 = elevation 
of 16–20 cmH2O; grade 5 = elevation ≥ 21 cmH2O
(defined as severe bronchospasm)]. A significant ele-
vation of airway pressure was defined as grade 1 or
above; resolution of the reaction was defined as the
airway pressure decreasing back to grade 0.
Statistical analysis
All statistical analyses were carried out using SPSS ver-
sion 15.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Patients were divided into a significant-airway-pressure-
elevation group (Group P) and a no-airway-pressure-
elevation group (Group N) according to whether or
not there was elevation of airway pressure after the
administration of prophylactic antibiotics. Continuous
data are presented as mean ± standard deviation, and
categorical data as counts with percentages.
The independent t test or χ2 test was used to com-
pare patients’ characteristics, patients’ medical history,
and variables related to the airway pressure of the 2
groups as appropriate. A p value < 0.05 was considered
to indicate statistical significance. In univariate analy-
sis, the odds ratio (OR) of each variance was estimated
using logistic regression analyses with enter mode. For-
ward stepwise logistic regression was performed with
preassigned p values equal to 0.05 for the further mul-
tivariate analysis. The OR of each variable was also
expressed with a 95% confidence interval (CI).
Results
In total, 185 patients who underwent general anes-
thesia in this period were investigated, 30 of whom
developed significant elevation of airway pressure
(Group P). All episodes of elevated airway pressure or
bronchospasm subsided after treatment, and all sur-
gery was completed without sequelae. The groups were
compared with respect to age, weight, height, under-
lying systemic diseases, and previous allergic history.
The intravenous and inhalational anesthetic agents ad-
ministered, and the interval between intubation and
antibiotic administration were also compared, and did
not differ significantly between groups (Table 1).
After the administration of cephalexin, specifically
Roles®, as a prophylactic antibiotic, 28 patients de-
veloped significant elevation of airway pressure (28 
vs. 43, p < 0.05), whereas with cefazolin (Cefa®; Taiwan
Biotech Co., Ltd., Taoyuan, Taiwan), only 2 patients
developed a reaction (2 vs. 68, p < 0.05). The degree
of airway pressure elevation in both of the patients
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who were administered Cefa® was grade 2, which 
was less severe than the degree of elevation in the pa-
tients administered Roles®, which ranged from grade
2 to grade 5 (Table 2). The mean duration of anti-
biotic administration was 19.00 ± 6.99 minutes in
Group P, compared with 31.07 ± 15.27 minutes in
Group N (p < 0.05). No differences were observed be-
tween the 2 groups when histories of allergy, asthma,
or chronic obstructive pulmonary disease were com-
pared (Table 1).
The crude and adjusted ORs of some potential risk
factors related to airway pressure elevation are displayed
in Table 3. In the univariate analyses, we found that
administration of Roles® was associated with significant
airway pressure elevation, and that Roles® was the most
significant factor related to airway pressure elevation
(crude OR, 16.930; 95% CI, 5.580–51.364). In con-
trast, the duration of antibiotic administration played
a protective role against airway pressure elevation
(crude OR, 0.905; 95% CI, 0.855–0.958). Other fac-
tors did not have a statistically significant influence on
airway pressure elevation. After logistic regression using
a forward stepwise model, Roles® was still found to be
the most significant risk factor related to airway pres-
sure elevation. The adjusted OR and 95% CI for Roles®
were 21.613 and 6.728–69.430, respectively. After
adjustment of all the other risk factors, only duration
of antibiotic administration was included (OR, 0.899;
95% CI, 0.848–0.953).
Discussion
Bronchospasm is an abnormal contraction of the
smooth muscle of the bronchi (bronchoconstriction),
resulting in an acute narrowing and obstruction of the
respiratory airway. It may present with increasing air-
way pressure, expiratory wheeze, prolonged exhalation,
or, in severe cases, complete silence on auscultation, and
may be associated with other life-threatening condi-
tions.5–7 During the course of anesthesia, severe bron-
chospasm may develop in patients with obstructive
airway diseases (such as asthma and chronic bronchi-
tis) and as a result of airway manipulation, irritation
of the tracheobronchial tree, or a host of other factors
that provoke histamine release.6 Often, the first mani-
festation of acute bronchospasm is a sudden rise in
peak inspiratory pressure. Meanwhile, wheezing may
be obvious on auscultation. However, difficulty in ven-
tilation, “silent chest” or lack of wheeze is an ominous
sign indicating extreme bronchospasm.7
Table 1. Demographic and anesthesia data of the enrolled patients*
Group P (N = 30) Group N (N = 155) p Total (N = 185)
Sex (male) 14 (47) 89 (57) 0.278 103 (55.68)
Age (yr) 56.30 ± 20.52 52.53 ± 19.48 0.337 53.14 ± 19.65
Body weight (kg) 61.45 ± 12.79 63.83 ± 15.42 0.428 63.44 ± 15.02
Body height (cm) 158.25 ± 10.02 161.70 ± 13.02 0.171 161.14 ± 12.62
BMI (kg/m2) 24.31 ± 3.35 24.15 ± 4.40 0.850 24.17 ± 4.24
Hypertension 13 (43) 49 (32) 0.213 62 (33.51)
Diabetes mellitus 8 (27) 21 (14) 0.181 29 (15.68)
CAD 2 (7) 6 (4) 0.719 8 (4.32)
COPD 0 (0) 2 (1) 0.532 2 (1.08)
Asthma 2 (7) 3 (2) 0.144 5 (2.70)
Allergic history 1 (3) 5 (3) 0.976 6 (3.24)
Isoflurane 12 (40) 70 (45) 0.602 82 (44.32)
Desflurane 11 (37) 44 (28) 0.364 55 (29.73)
Sevoflurane 7 (23) 40 (26) 0.776 47 (25.41)
Roles® 28 (93.33) 43 (27.74) 0.000† 69 (37.30)
Cefa® 2 (6.66) 68 (43.87) 0.000† 70 (37.84)
Interval (min) 35.27 ± 20.45 28.89 ± 27.39 0.228 29.92 ± 26.44
Duration (min) 19.00 ± 7.00 31.07 ± 15.27 0.000† 29.11 ± 14.93
*Data presented as n (%) or mean ± standard deviation; †p < 0.05. BMI = body mass index; CAD = coronary artery disease; COPD = chronic obstructive pul-
monary disease; Interval = interval between intubation and antibiotic administration; Duration = duration of antibiotic administration.
Table 2. Airway pressure elevation grades of Group P
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Causes of bronchospasm include mechanical-related
factors (kinking, endobronchial intubation, sputum,
secretion), patient-related factors (obesity, allergic re-
action, pulmonary edema, pneumothorax, aspiration of
gastric contents) and surgery-related factors (position
change, pneumoperitoneum) during the induction,
maintenance or emergence phase of anesthesia.6–8 A
structured approach to its diagnosis and management
could lead to earlier recognition and management.9
In this investigation, all cases of perioperative broncho-
spasm occurred during the maintenance phase of anes-
thesia. Thus, possible causes during the induction phase
(such as stimulus from tracheal intubation, hypersen-
sitivity from induction agents) could be ruled out.
Other mechanical-related factors and surgery-related
factors were ruled out by physical examination and
inspection of the endotracheal tubes. Most importantly,
the bronchospasms developed after the administration
of prophylactic antibiotics. During the interval be-
tween antibiotic administration and episodes of bron-
chospasm, no other medications were administered to
these patients. In other words, the prophylactic antibi-
otics were the only variables during this period.
A succession of bronchospasm cases in which in-
creasing airway pressure and expiratory wheeze oc-
curred during anesthesia came to our attention. In these
cases, the causes of bronchospasm during the mainte-
nance phase other than anaphylaxis were ruled out by
the anesthesiologists present. As already noted, it was
peculiar to observe a series of bronchospasm cases
within only a few weeks. We therefore hypothesized
that a major causative substance or other cofactors
might be involved. First, we conducted a brief survey
by reviewing the anesthesia records and questioning
surgeons to examine the possibility of any new med-
ications or procedures that were introduced, and found
that a new prophylactic antibiotic had indeed been
administered in most of the cases in which broncho-
spasm developed, according to the preliminary data.
The second step was to avoid the use of this antibiotic
by discussion with the surgeons who had prescribed
this prophylactic antibiotic during that period imme-
diately after our brief investigation had been conducted.
However, multiple medications are administered se-
quentially over a short period of time during general
anesthesia, making analysis of the relationship between
drug administration and clinical reactions difficult.
We hypothesized that this specific prophylactic antibi-
otic was the most likely causative substance which,
along with some contributive factors, induced an ana-
phylactic reaction. A comprehensive investigation was
performed in order to ensure patient safety and dis-
cern the causative substance and any contributive fac-
tors. We also advocate the collection and analysis of data
and discussion with surgeons as important responses
to such a series of uncommon events.
Table 3. Univariate and multiple logistic regression of potential risk factors related to airway pressure elevation
Univariate logistic Multiple logistic 
regression 95% CI regression 95% CI
crude OR adjusted OR
Sex (male) 0.649 0.296 1.422
Age 1.010 0.989 1.031
Body weight 0.989 0.964 1.016
Body height 0.982 0.956 1.099
BMI 1.015 0.931 1.107
Hypertension 1.654 0.745 3.673
Diabetes mellitus 2.303 0.908 5.842
CAD 1.762 0.338 9.179
COPD 0.000 0.000 0.000
Asthma 3.619 0.578 22.652
Allergy history 1.034 0.117 9.184
Desflurane 1.461 0.643 3.318
Isoflurane 0.810 0.365 1.794
Sevoflurane 0.875 0.349 2.194
Roles® 16.930 5.580 51.364 21.613* 6.728 69.430
Cefa® 0.091 0.021 0.397
Interval 1.007 0.995 1.020
Duration 0.905 0.855 0.958 0.899* 0.848 0.953
*p < 0.05. OR = odds ratio; CI = confidence interval; BMI = body mass index; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease;
Interval = interval between intubation and antibiotic administration; Duration = duration of antibiotic administration.
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Differentiating an allergic reaction from other symp-
toms occurring during anesthesia is difficult, as almost
all symptoms of allergic reactions are also common side-
effects of anesthesia. The fact that patients are cov-
ered with multiple surgical drapes, unconscious, and
unable to speak also makes correct and fast differen-
tial diagnosis during general anesthesia difficult. In
this retrospective investigation, we found that airway
and respiratory manifestations of perioperative anaphy-
laxis, including wheezing and increased airway pres-
sure, and even severe bronchospasm, without obvious
cutaneous manifestations were sole features of Group
P patients. Symptoms of allergic reaction during anes-
thesia, including cutaneous manifestations (erythema,
angioedema, urticaria), hypotension, collapse, cardiac
arrest, arrhythmia, and bronchospasm have been re-
ported with varying incidence.2,8,10–15 Cutaneous man-
ifestations are more common in episodes that are not
related to anesthesia;8 therefore, during general anes-
thesia, early cutaneous signs of anaphylaxis often go
unrecognized, meaning that bronchospasm and car-
diovascular collapse are frequently the first recognized
signs of perioperative anaphylaxis.1,2,11–16
We found that 28 of the 30 patients who devel-
oped significant elevation in airway pressure were
administered Roles® as their perioperative prophylac-
tic antibiotic. In the univariate analysis, the use of
Roles® was found to be associated with significant air-
way pressure elevation (Table 2). As a first-generation
cephalosporin, cephalexin is 1 of the most commonly-
used perioperative antibiotics. Roles® is 1 brand of
cephalexin, the use of which in our operating room
began in November 2007. Several other brands of
cephalosporin and cephalexin were also being used 
in our hospital, and prior to the use of this new brand
of cephalexin, we had experienced sporadic incidents
of anaphylactic reaction induced by antibiotics, such
as skin rash and cardiovascular collapse. But of note, 
it was curious that the suspected successive anaphy-
lactic reactions occurred after the use of Roles® was
introduced.
The incidence of perioperative anaphylaxis in pa-
tients under general anesthesia ranges from 1:5,000
to 1:25,000, with a mortality rate of 3.4% caused by
dramatic and unpredictable consequences.8,10,11,12 Peri-
operative anaphylaxis may be caused by a variety of
agents with varying incidences, including muscle relax-
ants, latex, antibiotics, opioids, intravenous anesthet-
ics, inhaled anesthetics, or local anesthetics.8,11,13–19
Antibiotics were implicated in 15.1% of perioperative
anaphylaxis cases in a 2-year survey conducted in
France.15 The reported frequencies vary considerably
among antibiotics. Of frequently-used antibiotics,
sulfonamides have been reported to most frequently
cause bronchospasm, and beta-lactams have also been
implicated (27% vs. 15%).20 In general, cephalosporin
anaphylaxis is rare, with a frequency of 0.0001–
0.1%.21–23 There have been a few case reports of 
anaphylactic reactions caused by penicillin and cefa-
zolin.21–23 However, reports of anaphylactic reactions
to intravenous cephalexin administration are rare.
Prophylactic antibiotics are administered to most
patients undergoing surgery under both regional and
general anesthesia. Patients who had received re-
gional anesthesia were excluded from this retrospec-
tive study because we did not observe any elevated
airway pressure and the patients, who were conscious,
did not complain of cutaneous or respiratory symp-
toms (such as cough and chest tightness). At first, 
we hypothesized that airway irritation or histamine-
releasing medications administered during general
anesthesia, including intravenous and inhalational an-
esthetics, were related to or contributed to the occur-
rence of this series of allergic reactions. Anaphylactic
reactions occurring within minutes of induction are
likely due to intravenous agents.14 Furthermore, bron-
chospasm can develop after endotracheal intubation
in patients who have a history of allergy, asthma, re-
active airway disease or cigarette smoking.6,7 Un-
derlying diseases, especially pulmonary diseases, are
also risk factors. The risk of an allergic reaction to
cephalosporins in patients with a history of penicillin
allergy may be up to 8 times greater than the risk in
those with no history of penicillin allergy.21,24 No dif-
ferences were observed between the groups when the
histories of allergy, asthma, and chronic obstructive
pulmonary disease were compared in our study, and
no allergic reactions to penicillin were documented or
reported. In other words, we failed to find any con-
tributing factors in those who developed an anaphy-
lactic reaction to Roles®. This may be due to the
number of cases being not large enough as, under the
principles of patient safety, we halted the administra-
tion of the suspected causative allergen after our brief
investigation.
We also found that the mean duration of antibi-
otic administration was shorter in Group P (19 min-
utes) than in Group N (31.07 minutes). Comparing
the 2 groups, it seems that the duration of administra-
tion played a protective role against bronchospasm.
Rapid intravenous administration of some antibiotics
is related to anaphylactic reaction, such as red man
syndrome due to vancomycin. The prophylactic anti-
biotic used in our patients was infused within the 
recommended administration time as listed in the
manufacturer’s instructions (5–10 minutes).
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The finding that rapid administration of Roles®
was the most significant factor related to broncho-
spasm has been communicated to the manufacturer.
The clinical response to our finding included halting
the use of any formulation of cephalexin or advocat-
ing slow administration of Roles®. We responded to
the results of this investigation by switching back to
other brands of cephalexin or cephalosporin that had
not previously caused severe bronchospasm to admin-
ister to patients undergoing general anesthesia.
It has been reported that drug formulation agents
(excipients) are involved in 9% of cases of perioperative
anaphylaxis.20 The mechanism of anaphylactic reac-
tion induced by Roles® is currently unknown. Drug
excipients and preservatives might be responsible for
the allergic reactions, and other contributing factors
may also be involved. Further study should be con-
ducted in an animal model to clarify the causes and
contributing factors.
In conclusion, rapid administration of Roles® was
highly likely to be the cause of perioperative anaphy-
lactic reaction presenting as bronchospasm with severe
elevated airway pressure in this study. Using Roles®
as the prophylactic antibiotic is not recommended in
patients undergoing general anesthesia. The clinical
responses to the cluster of anaphylactic reactions were
also presented. Further testing is required to identify
the mechanism of Roles®-induced bronchospasm dur-
ing general anesthesia.
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